








































Skeletal muscle mass and function decline gradually 
with age and become debilitating in 5-20% of elderly in 
populations aged over 65 [1-3]. This syndrome is 
commonly referred to as sarcopenia or physical frailty 
[4], and represents a major risk factor for falls, loss of 
independence in activities of daily living, nursing home 
admissions and, ultimately, mortality [1]. Sarcopenia is 
caused by multi-factorial endocrine and cellular 
processes that lead to defects in the contractile function 
of skeletal muscle. Reduced levels of anabolic 
hormones, degradation of the muscle contractile protein 
machinery, loss of regenerative capacity  and  stem  cell  
 
 







































function, altered neuronal excitation and mitochondrial 
dysfunction have all been associated with sarcopenia [5-
8]. However the exact causes and consequences of each 
of these aspects are not fully understood and require 
further mechanistic investigation at the molecular and 
cellular level in order to identify which mechanisms can 
be targeted for intervention. 
 
Altered neuromuscular communication during aging is 
receiving increasing attention as a potential cause of 
sarcopenia [8-10]. In mammals, motor innervation of 
skeletal muscle is propagated via motoneurons which 
elongate from the spinal cord along peripheral nerves to 
innervate highly specialized cholinergic synapses 



















Abstract:  Declining  muscle  mass  and  function  is  one  of  the  main  drivers  of  loss  of  independence  in  the  elderly.
Sarcopenia is associated with numerous cellular and endocrine perturbations, and it remains challenging to identify those




motoneuron  innervation,  and  reduced  excitability.  Remarkably,  muscle  loss  in  elderly  humans  also  differs  in  vastus
lateralis and  tibialis anterior muscles  in direct  relation  to neuromuscular dysfunction. By  comparing gene expression  in
susceptible and non‐susceptible muscles, we  identified a specific transcriptomic signature of neuromuscular  impairment.
Importantly,  differential  molecular  profiling  of  the  associated  peripheral  nerves  revealed  fundamental  changes  in
cholesterol biosynthetic pathways.  Altogether our results provide compelling evidence that susceptibility to sarcopenia is
tightly  linked  to  neuromuscular  decline  in  rats  and  humans,  and  identify  dysregulation  of  sterol  metabolism  in  the
peripheral nervous system as an early event in this process. 
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termed neuromuscular junctions (NMJs). Defects in the 
neuromuscular system have been demonstrated during 
aging in both rodents and humans [11-13]. In particular, 
loss of motoneurons and peripheral nerve axons as well 
as post-synaptic fragmentation of NMJs are hallmarks 
of aging that have been indirectly associated to impaired 
muscle functionality [11, 14-20]. Recent work has 
shown that qualitative alterations of the neuromuscular 
system occur before the loss of muscle mass, and 
suggests that a decline in motor unit numbers could be 
one of the early triggers in the pathophysiology of 
sarcopenia [6, 21, 22]. Therapeutic strategies to protect 
the neuromuscular system in the context of aging are, 
however, currently limited as only lifestyle 
interventions such as caloric restriction or exercise 
training have been demonstrated to slow-down the 
decline of NMJs with age [18].  
 
At the molecular level, NMJs are structured via a highly 
specialized molecular scaffold which enables nicotinic 
acetylcholine receptors (AchR) to localize specifically to 
the post-synaptic region [23]. AchRs cluster on post-
mitotic endplates in response to motoneuron inputs via a 
signaling cascade involving binding of neural agrin to the 
LRP4/MuSK complex. The transcription of genes 
controlling NMJ structure and function, including AchR 
subunits and Musk, is under tight spatial control through 
MuSK signaling in order to restrict expression of these 
genes specifically to the sub-synaptic myonuclei [24-26], 
while repressing it in extra-synaptic myonuclei [27]. 
Consequently, one of the molecular manifestations of 
sarcopenia is a gene signature for functional denervation 
and neuromuscular dysfunction [8], that most likely 
follows the de-repression of extra-synaptic NMJ gene 
transcription. However, whether neuromuscular 
perturbations are causal in the age-related decline in 
muscle mass and strength remains unclear [20]. 
 
In the present study we report that in rats and humans, 
age-related neuromuscular decline and the susceptibility 
to sarcopenia differ between muscles. This regional 
susceptibility can be used to uncouple sarcopenia from 
general aging mechanisms and uncover molecular and 
cellular events in muscle and nerve that are specific to 
sarcopenia. In particular, we identify cholesterol 
biosynthetic pathways to be strongly deregulated in 




Rat forelimb muscles are resistant to sarcopenia 
 
In order to characterize how aging differentially affects 
various locomotor muscles, we performed a cross-
sectional analysis of muscle mass in male Wistar rats, 
where skeletally mature adult controls of 8 months of 
age were compared to aged animals ranging from 18 
months to 24 months. As previously reported [8], 
hindlimb muscle mass progressively declined with age, 
reaching approximately 50% atrophy by 24 months of 
age (Figure 1A). Fast type II myofibers are more 
susceptible to muscle wasting with age [28, 29]. 
Consistently, age-dependent muscle atrophy was more 
pronounced in fast twitch than slow twitch muscles. 
Nevertheless, all hindlimb muscles analyzed had a 
similar kinetic of muscle mass decline with age 
regardless of their fiber type composition and of their 
contractile involvement in planta- or dorsiflexion, 
suggesting that a mechanism independent of the 
contractile phenotype could be an upstream determinant 
of the susceptibility to age-related muscle atrophy. In 
contrast, forelimb muscles were protected from age-
related muscle atrophy and showed stable muscle mass 
even at old age (Figure 1B). This striking differential 
phenotype between hind- and forelimbs suggests that 
anatomical differences are the primary driver for the 
susceptibility to sarcopenia. In order to uncover the 
molecular and cellular mechanisms underlying this 
differential susceptibility to sarcopenia, we separated 
the decline in hindlimb muscle mass in 2 phases: an 
early-sarcopenic phase between 18-20 months of age, 
where the decline is mild; and a sarcopenic phase 
between 22-24 months of age where the decline is 
severe. We then analyzed the fiber size distribution of 
tibialis anterior (TA) and biceps brachii as prototypical 
hind- and forelimb muscles, respectively. Fiber cross-
sectional area specifically decreased with advancing age 
in TA while remaining stable in biceps brachii, further 
demonstrating that forelimb muscles do not undergo 
aged-related atrophy (Figure 1C-D). Finally, analysis of 
fiber types revealed that the proportion of slow fibers 
had slightly increased with age in TA, but not in biceps 
brachii (Supplementary Figure 1). Cross-sectional area 
analysis for each fiber type confirmed that fast type IIB 
fibers were the most prone to age-induced atrophy, and 
fiber IIB atrophy was only observed in the TA and not 
the biceps brachii of aged sarcopenic rats 
(Supplementary Figure 1).  
 
Sarcopenia is diagnosed clinically using both muscle 
mass and function, with gait speed used as one of the 
clinical measures for function [30]. In order to assess 
muscle function in the aging rats, we performed a 
catwalk analysis to evaluate the natural gait of the 
animals. Gait speed was significantly decreased with age 
in early sarcopenic rats, due to both a shorter stride length 
and increased stand time (i.e. the duration of paw contact 
on the ground) (Figure 2). Differential analysis of hind- 
and forelimbs further revealed that aged rats have more 
difficulties to lift their hindlimbs, but not  their  forelimbs,  
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as indicated by a reduced swing time with age that is 
specific for hindlimbs (Figure 2B). Muscle function is 
therefore impaired in aged rats, and differences in the 
susceptibility to muscle wasting between forelimbs and 



















































deficits. Altogether, these data demonstrate that rat 
sarcopenia is highly regional within the body and that 
the difference in the susceptibility to sarcopenia can be 





















































Figure 2. Gait  analysis  reveals  impaired hindlimb  function with  age. Gait  parameters were  analyzed  using  a
catwalk device in 8‐10 months old (adult) and 18‐20 months old (early sarcopenic) rats. (A) Gait speed and stride length
(B) Time rats keep their  front or hind paws  in contact with the surface  (stand time), or not  in contact with the surface
(swing  time).  (C) Representative paw prints  from adult and early  sarcopenic  rats.  LH:  left hind, RH:  right hind,  LF:  left
front, RF: right front. For all graphs n=9‐15 per group. * p<0.05 ** p<0.01 *** p<0.001 with a one‐way ANOVA test. 
  


































One major difference between hindlimb and forelimb 
muscles is that they are innervated by fully distinct sets 
of nerves, which emanate from different regions of the 
spinal cord. To test whether differential neuromuscular 
dysfunction could explain the different susceptibility to 
sarcopenia, we assessed electromyographic responses in 
a subset of hindlimb and forelimb muscles from adult, 
early-sarcopenic and sarcopenic rats. The maximal 
amplitude of the compound muscle action potential 
(CMAP) was recorded with needle electrodes inserted 
in muscles from the hindlimb and forelimb, after 
stimulating the sciatic and radial nerves, respectively. 
The maximal CMAP amplitude progressively declined 
with advancing age in the hindlimb gastrocnemius and 
TA muscles (Figure 3A-B) but was fully preserved in 
the forelimb biceps brachii and triceps brachii muscles 
(Figure 3C-D). These results demonstrate that 
neuromuscular transmission declines specifically with 
age in muscles susceptible to sarcopenia, and suggests 
that a causal relationship may exist between impaired 



































Transcriptomic profiling reveals a neuromuscular 
signature specifically regulated in muscles 
susceptible to sarcopenia 
 
Given the regional susceptibility to sarcopenia in rats 
(Figure 1), differential profiling of hindlimb and 
forelimb muscle gene expression by RNA sequencing 
during aging provided a way to dissociate the pathways 
which are specifically regulated during sarcopenia only 
in hindlimb muscles, from those commonly regulated 
with age in both hindlimb and forelimb muscles. Many 
genes were progressively regulated with age in 
gastrocnemius with more than 3000 genes regulated 
during early-sarcopenia and more than 6000 genes 
regulated in sarcopenic hindlimb muscle (Figure 4A). 
Gene ontology analyses on aged gastrocnemius muscles 
confirmed that aging alters important biological 
processes such as neuromuscular function, extra-cellular 
matrix remodeling & fibrosis, energy homeostasis & 
mitochondrial function, and inflammation 
(supplementary table S1), in agreement with previously 
reported molecular profiling of sarcopenia in the 
Figure 3. Neuromuscular transmission declines specifically with age in hindlimb but not forelimb muscles in rats. Compound
muscle action potential (CMAP) was measured by electromyography  in hindlimb (A) or forelimb (C) muscles of adult, early‐sarcopenic or
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hindlimb [6, 8]. Strikingly, in the triceps brachii muscle, 
only 196 genes were significantly regulated with age, 
out of which almost all were regulated at the oldest age 
(Figure 4B). In addition, nearly all genes for which 
expression was affected by aging in triceps brachii were 
also similarly affected by aging in gastrocnemius 
(Figure 4B). This highly specific molecular signature of 
aging in gastrocnemius over triceps brachii therefore 
confirmed that rat sarcopenia is also regional at the 
molecular level and demonstrated that molecular 
perturbations in muscle are linked to sarcopenia rather 












































genes differentially regulated by age in gastrocnemius 
and triceps brachii). Gene ontology analysis of the 
interaction between age and muscle type, which 
uncouples sarcopenia from aging, demonstrated that 
sarcopenia specifically alters neuromuscular function, 
extra-cellular matrix remodeling and energy 
homeostasis (supplementary table S3). In contrast, 
genes commonly regulated in both muscles map to 
inflammation and immune response categories 
(supplementary table S4), suggesting that at least this 
subset of chronic inflammatory signaling is not 













































Figure  4.  RNA‐sequencing  reveals  specific  changes  in  hindlimb muscles with  age.  RNA‐Seq  profiling  was
performed comparing gastrocnemius and  triceps brachii  from adult, early sarcopenic or sarcopenic  rats.  (A) Venn diagrams of
















































Aging promotes a global up-regulation of many genes 
controlling NMJ assembly and function in hindlimb 
muscles, likely through de-repression of extra-synaptic 
gene inhibition [8]. Given that both neuromuscular 
decline and altered gene expression correlated with 
regional muscle wasting, we further analyzed the 
molecular perturbations in muscle linked to the NMJ. 
When we focused on genes regulated with age 















































GO:0031594), we could identify 2 major clusters of 
genes either up- or down-regulated with age 
specifically in gastrocnemius (Figure 4C). Importantly, 
none of these genes were regulated with age in triceps 
brachii in the genome wide profiling and in the follow-
up validation by quantitative PCR (Figure 4D), 
demonstrating that deregulation of neuromuscular 
genes during aging occurs specifically in the muscle 





























































Neuromuscular defects with age are directly 
associated with the susceptibility to sarcopenia 
 
The molecular and electrophysiological defects of 



















































forelimbs were then investigated at the cellular level. 
Increased fragmentation of the neuromuscular endplates 
through dispersion of acetylcholine receptors is believed 
to be a hallmark of impaired NMJ functionality [31]. 
















NM_001107709 Ap4b1 adaptor-related protein complex 4, beta 1 subunit -0.377 -0.352 0.537 3.894E-04 
NM_001107839 Rc3h2 ring finger and CCCH-type domains 2 -0.507 -0.093 0.572 3.894E-04 
NM_001270630 Bdnf brain-derived neurotrophic factor 0.098 -0.033 0.896 6.835E-03 
NM_001104613 Hnrnpa2b1 heterogeneous nuclear ribonucleoprotein A2/B1 -0.102 -0.541 0.587 1.023E-02 
NM_017268 Hmgcs1 3-hydroxy-3-methylglutaryl-CoA synthase 1 (soluble) -0.726 0.004 -0.805 1.023E-02 
NM_053539 Idi1 isopentenyl-diphosphate delta isomerase 1 -0.853 -0.011 -0.808 1.023E-02 
XR_145741 LOC100909757 uncharacterized LOC100909757 0.391 0.235 -0.560 1.023E-02 
NM_013092 Cma1 chymase 1, mast cell -0.595 0.689 -1.090 1.023E-02 
XM_003751331 LOC685158 similar to CG8138-PA 0.760 0.128 1.058 1.023E-02 
NM_019300 Cpa3 carboxypeptidase A3, mast cell 0.100 0.791 -1.170 1.515E-02 
NM_053554 Picalm phosphatidylinositol binding clathrin assembly protein -0.425 -0.196 0.463 1.687E-02 
NM_053589 Rab14 RAB14, member RAS oncogene family 0.365 0.050 -0.443 1.915E-02 
NM_001170487 Myrf myelin regulatory factor -0.308 -0.192 0.585 1.915E-02 
NM_134383 Elovl6 ELOVL fatty acid elongase 6 -0.959 -0.059 -0.838 1.915E-02 
NM_001257349 Gng2 guanine nucleotide binding protein (G protein), gamma 2 -0.739 -0.277 0.853 1.915E-02 
NM_012845 Ms4a2 membrane-spanning 4-domains, subfamily A, member 2 0.048 0.819 -1.000 1.915E-02 
NM_001277668 Mcpt1l1 mast cell protease 1-like 1 0.065 0.454 -0.966 2.140E-02 
NM_001012738 Ckmt1b creatine kinase, mitochondrial 1B -0.623 -0.494 -0.811 2.140E-02 
NM_017053 Tacr3 tachykinin receptor 3 -1.318 -1.472 1.056 2.140E-02 
NM_019238 Fdft1 farnesyl diphosphate farnesyl transferase 1 -0.772 -0.036 -0.674 2.213E-02 
NM_012941 Cyp51 cytochrome P450, family 51 -0.620 0.041 -0.604 2.618E-02 
NM_001107278 Fndc3a fibronectin type III domain containing 3a 0.448 0.127 -0.435 2.734E-02 
NM_020100 Ramp3 receptor (G protein-coupled) activity modifying protein 3 1.021 0.130 0.766 3.313E-02 
NM_001077356 Clca4l chloride channel calcium activated 4-like 0.646 0.105 -0.578 3.313E-02 
NM_053539 Idi1 isopentenyl-diphosphate delta isomerase 1 -0.990 -0.129 -0.838 3.356E-02 
NM_172023 Osbpl1a oxysterol binding protein-like 1A -0.369 -0.090 0.350 3.801E-02 
NM_012941 Cyp51 cytochrome P450, family 51 -0.664 0.027 -0.635 3.801E-02 
NM_001025414 Hars histidyl-tRNA synthetase -0.365 -0.333 0.557 3.801E-02 
NM_019180 Tpsb2 tryptase beta 2 0.277 0.716 -1.118 3.801E-02 
NM_031091 Rab3b RAB3B, member RAS oncogene family -0.119 0.023 0.958 3.801E-02 
NM_022211 Fgf5 fibroblast growth factor 5 0.570 0.050 1.403 3.816E-02 
NM_001107052 Arl4d ADP-ribosylation factor-like 4D -1.487 0.223 -0.984 3.866E-02 
NM_013034 Slc6a4 solute carrier family 6 (neurotransmitter transporter), member 4 -0.030 0.297 -0.849 3.866E-02 
XM_001059693 Tmcc2 transmembrane and coiled-coil domain family 2 -0.680 -0.620 0.497 4.842E-02 
NM_001108202 Dlk2 delta-like 2 homolog (Drosophila) -0.285 -0.165 0.439 4.842E-02 
XM_001073064 LOC686240 N(alpha)-acetyltransferase 16, NatA auxiliary subunit 0.297 0.086 -0.385 4.855E-02 
NM_022618 Akap6 A kinase (PRKA) anchor protein 6 -0.154 -0.242 0.506 4.855E-02 
NM_001106899 Plekhb2 pleckstrin homology domain containing, family B (evectins) member 2 -0.224 -0.147 0.498 4.988E-02 
Model: Gene ~ β0 + β1Age + β2Nerve + β3Age:Nerve 
Reference group: adult radial nerve 
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muscles was assessed by isolating fiber bundles from 
biceps brachii and Extensor Digitorum Longus (EDL), 
respectively, and scoring the level of fragmentation from 
the images where acetylcholine receptors were stained 
with fluorescently labeled α-bungarotoxin. The 
fragmentation level of the hindlimb EDL muscle 
increased with age from ~20% in adult muscle to ~70% 
in sarcopenic muscle (Figure 5A), consistent with pre-
vious reports demonstrating hindlimb NMJ fragmentation 













































proportion of fragmented junctions remained stable at 
all ages (Figure 5B), despite a much higher baseline 
fragmentation that likely arises from inherent NMJ 
architecture in different muscles [32, 33]. In order to 
confirm that differential fragmentation in hindlimb and 
forelimb muscles were associated with functional 
differences during neuromuscular aging, we performed 
retro-labeling studies by injecting the fluorescent 
retrotracer fluorogold into the gastrocnemius and the 
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ing labeled motoneurons in the spinal cord (Figure 5C). 
The number of labeled spinal cord motoneurons 
projecting to the gastrocnemius hindlimb muscle declined 
dramatically by more than 50% in sarcopenic vs adult 
rats, while motoneurons innervating the triceps brachii 
maintained a normal connectivity with age (Figure 5D). 
These results demonstrate that both the morphology of 
NMJs and the connectivity of motoneurons from the 
spinal cord are specifically altered in sarcopenic hindlimb 
muscles. Taken together, they further highlight a tight 
correlation between age-related neuromuscular decline 
and sarcopenia, which suggests that alterations in the 
neuromuscular system may be causal in the initiation and 
progression of sarcopenia. 
 
Cholesterol biosynthesis declines differentially in 
nerves according to muscle susceptibility to 
sarcopenia 
 
Our results demonstrated that defects in the connectivity 
from the spinal cord to muscle are correlated with 


































To further investigate whether intrinsic molecular 
defects in nerves could contribute to the susceptibility to 
sarcopenia, we performed a gene expression analysis 
comparing hindlimb sciatic nerve to forelimb radial 
nerve in adult and sarcopenic animals. As shown in 
Figure 6A, many genes were regulated with age in both 
nerves, providing a general signature of nerve aging. 
Gene ontology analysis of genes differentially regulated  
with age in the 2 nerve types (i.e. the interaction term of 
the two by two factorial design) converged on many GO 
terms associated with cholesterol biosynthesis (Figure 
6B). Nerve electric signal conduction and velocity are 
largely dependent on the lipid-rich myelin sheath 
produced by  Schwann cells around the motoneuron 
axons [34]. Cholesterol is the major constituent of 
myelin as it accounts for 25% of total myelin lipids, and 
is essential for proper myelin synthesis and maintenance 
[35, 36]. Cholesterol is synthesized via a 37-step 
process regulated by key rate-limiting enzymes such as 
HMG-CoA reductase, squalene epoxidase and farnesyl-
PP-synthase. When looking specifically at the gene 
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with age in both sciatic and radial nerves, which 
decrease was significantly stronger in the sciatic nerve 
(Figure 6C). These data suggest that cholesterol 
synthesis is impaired with age in correlation with 
neuromuscular defects, suggesting that defects in 
cholesterol synthesis could be an early event in the age-
related neuromuscular dysfunction. Interestingly, a 
substantial number of genes showed stronger regulation 
with age in the sciatic nerve (Table 1), thereby 
providing potential mechanisms that could drive the 
differences in neuromuscular severity between 
hindlimbs and forelimbs. Of particular interest, some 
neurotrophic factors and regulators of myelination such 
as Bdnf and Fgf5 were specifically up-regulated with 
age in the sciatic but not the radial nerve (Figure 6D), 
most likely because of compensatory mechanisms that 
are secondary to the severity of nerve alterations. The 
stronger up-regulation of the neurotrophin receptor 
p75NTR in aged sciatic nerve further confirmed that 
nerves afferent to sarcopenic muscles re-activate 
neurotrophic gene expression programs as p75NTR 
controls myelination development and is upregulated in 
demyelinating motoneuron diseases and nerve injury 
[37]. 
 
Neuromuscular dysfunction correlates with loss of 
muscle mass in elderly humans 
 
Our results in the rat model of sarcopenia revealed a 
strong correlation between neuromuscular dysfunction 
and skeletal muscle atrophy during aging. To test this 
hypothesis in humans, we evaluated muscle mass and 
CMAP in the vastus lateralis, a muscle that is 
particularly susceptible to sarcopenia, and tibialis 
anterior, which does not normally experience muscle 
mass decline with advancing age [38]. The decline in 
muscle size with increasing age in the vastus lateralis 
(VL) muscle was strongly correlated to decreased 
CMAP amplitude, demonstrating that both loss of 
muscle and neuromuscular defects affect this muscle in 
the elderly (Figure 7A-B). In the tibialis anterior, 
however, neither muscle size nor CMAP amplitude 
significantly decreased with increasing age (Figure 7C-
D). These results demonstrate that, similar to our 
observations in the rat, human skeletal muscles with 





Loss of muscle mass and strength is a disabling factor in 
the aging population for which the prevention and 
therapeutic options are currently limited. One of the 
challenges to maintain mobility and physical function in 
elderly arises from the overlap of a wide range of 
molecular, cellular, endocrine and nutritional 
perturbations occurring with age. These multi-factorial 
contributions to sarcopenia overlap within individual 
patients, and can be confounded by other manifestations 
of aging that do not directly play a role in muscle 
pathophysiology. 
 
Our study establishes a direct and robust association 
between neuromuscular dysfunction and sarcopenia and 
characterizes molecular and cellular perturbations of the 
neuromuscular system that are specifically altered 
during sarcopenia. In particular, we demonstrate that the 
susceptibility to sarcopenia differs across different 
muscles within individuals, both in rats and humans. In 
humans, the vastus lateralis muscle cross-sectional area 
was decreased by approximately 40% in the elderly 
cohort investigated, which is in line with our previous 
findings in older men [39]. Importantly, the decline in 
vastus lateralis size in aged individuals directly 
correlated with the decline in CMAP amplitude 
measured during electrophysiological assessments. In 
contrast, the tibialis anterior muscle showed 
preservation of both muscle cross-sectional area and 
CMAP amplitude.  The CMAP is a clinical assessment 
of neuromuscular function that is widely used to 
examine a range of motoneuron and muscle diseases 
because it indicates the sum of excitable tissue, 
although it does not necessarily indicate the numbers of 
motoneurons per se. Interestingly, both the vastus 
lateralis (VL) and the TA muscles have been shown to 
lose motor units with advancing old age in humans [40]. 
Therefore, the relative preservation of muscle mass and 
CMAP in TA compared with vastus lateralis (VL) 
suggests that the susceptibility to muscle loss and thus, 
sarcopenia, can be mediated by local nerve-muscle 
interactions. The direct correlation between sarcopenia 
and neuro-muscular dysfunction was also observed in 
Wistar rats, where muscle mass, gait and neuromuscular 
function specifically declined in all hindlimb but not 
forelimb muscles that were analyzed. Interestingly, a 
similar regional decline in muscle mass has also been 
reported in humans when considering the entire 
musculature of the limb, as muscle mass declined faster 
with age in the legs than in the upper body [41]. 
Consistent with previous reports in various strains [7, 
28], all rat hindlimb muscles including tibialis anterior 
were affected by sarcopenia, possibly differing from the 
human phenotype because of rodent-specific posture 
and locomotion. Altogether, the fact that both rats and 
humans show regional decline in muscle mass across 
the different anatomical locations demonstrates that 
endocrine and systemic factors alone are not the 
primary mechanism driving sarcopenia. Together with 
the observation that neuromuscular decline precedes 
loss of muscle mass [21], our results on the tight 
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association of neuromuscular function and sarcopenia in 
symptomatic and non-symptomatic muscles of a given 
individual strongly suggest that neuromuscular 
dysfunction could be one of the primary drivers of 
sarcopenia. 
 
The absence of sarcopenia in the forelimb muscles of 
aged rats also provides a unique model to tease out the 
molecular and cellular processes that are deregulated 
during aging without directly contributing to sarcopenia 
from those that are directly associated to the loss of 
muscle mass during aging. At the molecular level, 
inflammatory gene signatures were changed with age in 
both the muscles prone and resistant to sarcopenia. In 
contrast, gene networks for neuromuscular function, 
mitochondria and extra-cellular matrix remodeling and 
fibrosis were primarily altered with age in the muscle 
prone to sarcopenia. Experimental models of 
denervation via nerve resection in young animals have 
demonstrated that loss of motoneuron innervation 
impairs mitochondrial function and alters the extra-
cellular matrix both at the gene expression and 
functional level [42-45]. Thus, it is likely that 
neuromuscular alterations are priming events in the 
initiation of sarcopenia and lead to downstream 
perturbations of muscle metabolism and fibrosis by 
perturbing muscle contractibility. In addition, NMJ 
fragmentation and motoneuron retro-labeling clearly 
demonstrated that age specifically affects the 
neuromuscular system only in the muscles sensitive to 
sarcopenia, further highlighting that neuromuscular 
dysfunction is most likely required to initiate the loss of 
muscle mass.  
 
The effects of age on the neuromuscular system were 
observed at the level of the NMJ as previously reported 
[18, 32], but also on the direct connectivity of 
motoneurons projecting from the spinal cord to muscle 
fibers. Axons themselves are also affected by aging as 
axonal diameter increases while myelination is 
adversely affected in old sciatic nerves [21, 46, 47]. 
Interestingly, these nerve fiber perturbations during 
aging seem restricted to nerves innervating hindlimb 
muscles while sparing nerves innervating the forelimb 
[47], suggesting that perturbations in the nerve could be 
one of the upstream determinants of sarcopenia. The 
priming causes leading to differential functional 
manifestations of aging in the different nerves still 
remain unclear. One possibility is that proximal to distal 
location of motoneuron cellular bodies in the spinal 
cord could modulate their sensitivity to aging since the 
sciatic nerve, which is more sensitive to aging, spans 
from the lumbar region, while the radial nerve spans 
from the cervical region. Another possibility is that 
surviving nerves within muscles that are less susceptible 
to sarcopenia have a higher capacity to perform axonal 
sprouting and re-innervate fibers in order to compensate 
for the loss of motoneurons. It is not yet clear which 
neuromuscular environments might favor reinnervation 
over loss of fibers, but there is evidence of such muscle-
specific responses in humans. For instance, motoneuron 
loss in the vastus lateralis (VL) [40] is accompanied by 
extensive fiber loss [29], while motoneuron loss of in 
human TA is almost completely compensated by fiber 
reinnervation resulting in fewer, but considerably larger, 
motor units [48] and no loss of muscle mass (Fig 7).  
 
At the molecular level, we identified transcriptional 
signatures of nerve aging that are specific to the sciatic 
over the radial nerve. Gene expression analysis has 
previously suggested a role for lipid metabolism and 
inflammation as mechanisms of nerve aging [46]. Our 
analyses of sciatic and radial nerves unequivocally 
identified cholesterol biosynthesis as the key pathway 
differentially regulated in the sciatic nerves innervating 
the sarcopenia-prone leg muscles. All rate limiting 
enzymes of cholesterol biosynthesis were down-
regulated with age with a larger amplitude in the sciatic 
than the radial nerve. Cholesterol is the major lipid 
constituent of myelin and genetic deletion of cholesterol 
biosynthetic enzymes or cholesterol sensors leads to 
strong hypo-myelination phenotypes and locomotor 
deficits [49, 50]. In addition, statins, which are widely 
used clinically to mitigate cardiovascular risks by 
reducing cholesterol levels through HMG-CoA 
reductase inhibition, have been proposed to increase the 
risk for peripheral neuropathy [51], on top of their well-
known side effects on muscle [52]. Down-regulation of 
cholesterol biosynthesis in aged nerves therefore likely 
alters myelination to induce neuromuscular dysfunction 
and sarcopenia. The gene signature specifically 
regulated with age in the sciatic nerve was also enriched 
in genes coding for secreted factors such as BDNF and 
FGF5, as well as the neutrophin receptor p75NTR, 
raising the possibility that neurotrophic paracrine 
signaling could also contribute. Given that these factors 
have previously been shown to protect from neuro-
muscular dysfunction or to be induced upon denervation 
[37, 53-55], it is, however, more likely that these 
molecular perturbations are compensatory adaptations 
secondary to the effects that drive neuromuscular aging. 
Given that compensatory mechanisms at the gene 
expression level often indicate functional deficiencies, 
these observations could highlight local loss of 
neurotrophic input via either lower growth factor 
secretion or intra-cellular growth factor resistance. 
 
Altogether, our study brings comprehensive evidence 
that the severity of sarcopenia is tightly linked to 
neuromuscular dysfunction in rats and humans, with 
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direct evidence in both species that susceptibility to 
sarcopenia is strongly influenced by local rather than 
systemic cues. Electrophysiological measurements, 
NMJ morphology, and molecular profiling all converge 
to demonstrate that neuromuscular input plays a key 
role in the susceptibility to sarcopenia, and that altered 
cholesterol metabolism in aged nerves is a mechanism 




Animal experiments. All experimental procedures on 
animals were in agreement with Swiss and EU ethical 
guidelines and approved by the local animal 
experimentation committee of the Canton of Vaud 
(license number VD2630). Male Wistar rats aged 8 
months to 24 months were obtained from Janvier Labs 
(Le Genest-Saint-Isle, France). Upon arrival all animals 
were housed by two in standard type 4 cages with ad 
libitum access to food and water on a 12 hour light/dark 
cycle at a temperature between 20-24°C and a relative 
humidity between 50-60%. All rats labeled by age were 
grouped by date of birth within one month, and further 
grouping was then based on the muscle phenotype in 
hindlimbs under the following categories: adult (8-10 
months of age), early-sarcopenic (18-20 months of age), 
and sarcopenic (22-24 months of age). Rats were 
sacrificed by exsanguination under isoflurane anesthesia 
and skeletal muscles were dissected free of fat, weighed 
and snap frozen in liquid nitrogen or processed for 
histology as described below. A piece of about 1cm of 
sciatic and radial nerves was dissected out from the 
mid-thigh or arm region and snap frozen in liquid 
nitrogen. 
 
Electromyography (EMG) measurements were 
performed on rats under isoflurane anesthesia. The left 
limbs were shaved and recording needle electrodes 
(twisted pairs, wire 150cm, needle 0.4 x 13mm, 
Neurolite, Switzerland) were sequentially placed into 
the gastrocnemius, tibialis anterior, triceps brachii and 
biceps brachii muscles. Supra-maximal electric 
stimulation was achieved via stimulating needle 
electrodes sequentially placed around the sciatic nerve 
and the radial nerve, and the resulting compound 
muscle action potential (CMAP) was recorded using the 
Keypoint software (Neurolite, Switzerland). 
 
Gait parameters were measured using the Catwalk XT 
system (Noldus, Netherlands). Animals were placed to 
spontaneously walk on a glass lane with tangential 
illumination and each step was recorded by detecting 
light diffraction using a camera below the lane. At least 
3 runs per animal were acquired with 10 minutes break 
in between. Locomotion patterns and gait speed were 
then analyzed from smooth runs, which were defined as 
runs during which the rat maintained constant speed for 
at least 3-4 prints per paw, using the automated Catwalk 
analysis software. All runs were required, manually 
edited for correct detection of the paws. 
 
Immunofluorescence staining and microscopy. For fiber 
type analysis, tibialis anterior and biceps brachii were 
frozen in isopentane cooled in liquid nitrogen, stored at 
-80°C and cryo-sectioned at 10μm. Sections were 
incubated 2h in blocking solution made with 4% IgG-
free bovine serum albumin (001-000-162, Jackson 
immunoresearch) + 1% fetal bovine serum in PBS and 
subsequently incubated with mouse MHC2B (clone 
BFF3, DSHB) and rabbit laminin (L9393, Sigma 
aldrich) antibodies overnight. After washing, sections 
were incubated with donkey anti-mouse-IgM-Cy3 (715-
165-020, Jackson immunoresearch) + goat anti-rabbit-
A405 (A-31556, Thermo Fisher) secondary antibodies 
for 1h. A second round of incubations were then 
performed using MHC2A (clone SC71, DSHB) + 
MHC1 (clone BAD5, DSHB), and then goat anti-
mouse-IgG1-A647 (A-21240, Thermo Fisher) + goat 
anti-mouse-IgG2b-A488 (A-21141, Thermo Fisher). 
Images were acquired using a slide scanner (VS-120, 
Olympus) and analyzed using an in-house MetaXpress 
journal (Molecular Devices, Sunnyvale, USA). Briefly, 
fibers were segmented based on laminin staining using a 
combination of morphological operators and 
thresholding. Segmentation results were manually 
controlled and corrected prior to create the final 
segmentation masks and extract individual fiber cross-
sectional area. Intensity thresholds for fiber type 
staining were manually chosen for each image 
individually before final quantification. Fibers where 
the average intensity in the channel of interest was 
above the threshold were annotated positive for this 
specific marker. Fibers that were negative for MHC1, 
2A and 2B were considered positive for MHC2X. 
Subsequent data processing was performed by a custom 
workflow using KNIME Analytic Platform 
(http://www.knime.org) [56].  
 
For neuromuscular junction analyses, muscles were 
pinned on cork in PBS and injected with α-
bungarotoxin-A488 (1:5000, B-13422 Thermo Fischer) 
for 30min to stain for acetylcholine receptors. Muscles 
were then rinsed with PBS and injected with 2% 
paraformaldehyde solution (P6148, Sigma Aldrich) for 
15min, rinsed again and stored at 4°C. Muscles were 
then separated into bundles of 20-30 fibers, mounted 
with fluorescence mounting medium (S302380, Dako) 
and pressed overnight at 4°C. Images were acquired on 
a Leica DMI 6000B microscope. For each muscle, 
approximately 50 neuromuscular junctions were imaged 
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and each junction was classified into 3 classes (1-2 
fragments, 3-4 fragments or ≥5 fragments) according to 
the number of fragments counted manually. 
 
Motoneuron retrotracing study. Rats were anesthesized 
using isoflurane and the right legs were shaved and 
disinfected with ethanol. Fluorogold (Fluorochrome 
LLC) was diluted at 2% (w/v) and injected into the 
gastrocnemius and triceps brachii at 4 to 6 points of 
injection. The total volume of injection was 60-80 μL per 
muscle. Ten days later, animals were sacrificed by 
intracardial perfusion of paraformaldehyde and the spinal 
cord was dissected out, placed in paraformaldehyde 
solution overnight at 4°C and subsequently placed in 
20% sucrose solution for 3-4 days. The cervical and 
lumbar regions of each spinal cord were then removed 
and frozen in OCT embedding medium (361603E, VWR 
Chemicals). Each sample was cryo-sectioned at 40μm on 
its entire length and 1 out of 4 sections were examined to 
count the number of labeled motoneurons. 
 
Gene expression profiling.  
Muscle RNA-Seq analysis. Total RNA was extracted 
using the miRNeasy Mini Kit (Qiagen) according to the 
manufacturer’s instruction. RNA quantity was measured 
with Ribogreen (Life Technologies) and RNA quality 
was assessed on a Bioanalyzer (Agilent Technologies). 
Sequencing libraries were prepared from 250ng total 
RNA using the TruSeq RNA Library Preparation Kit v2 
following the manufacturer’s protocol. The procedure 
was automated on a Sciclone NGS Workstation (Perkin 
Elmer). Purified libraries were quantified with Picogreen 
(Life Technologies) and the size pattern was controlled 
with the DNA High Sensitivity Reagent kit on a LabChip 
GX (Perkin Elmer). Libraries were then pooled and 
clustered at a concentration of 8pmol on a v3 paired-end 
sequencing flow cell (Illumina). Sequencing was 
performed for 2 x 100 cycles on a HiSeq 2000 strictly 
following Illumina’s recommendations. Fastq files were 
mapped to the Rattus Norvegicus genome Rnor_6 with 
the alignment software RNAStar (version 2.3.0) using the 
following parameters: outFilterMultimapNmax = 3, 
outFilter MismatchNoverLmax = 0.3, outFilterMulti 
mapScore Range = 1. Mapped sequences with mapping 
scores lower than 30 (samtools-0.1.19 with option -q 30) 
were filtered out from further analysis, and mapped 
sequences that passed QC criteria were exported as one 
bam file per sample. The number of reads mapped within 
genes was quantified by HTSeq (option union, version 
HTSeq-0.5.4p3). Genes with very low counts (less than 
20 reads in each sample) were discarded. The gene 
counts were normalized using edgeR TMM (trimmed 
mean of M values) prior to voom (variance modelling at 
the observational level) analysis in Limma [57, 58]. We 
provided an estimate of the within-animal correlation via 
the duplicate Correlation function available in Limma 
since we had two muscles from each animal [59]. The 
voom method was used to estimate the mean-variance 
relationship of log2 counts per million (log-cpm) for each 
sample. These estimates were taken into consideration by 
the empirical Bayes Limma models. We analyzed the 
data set as a two (muscle types: triceps brachii and 
gastrocnemius) by three (age categories: 8, 18, and 24 
months) factorial design. Raw data are available in GEO 
(http://www.ncbi.nlm.nih.gov/geo/) under accession 
number GSE78702. 
 
Nerve micro-array analysis. Total RNA was extracted 
using the miRNeasy Mini Kit (Qiagen) according to the 
manufacturer’s instruction. The quality of RNA samples 
was checked using the Standard Sensitivity RNA 
Analysis Kit on a Fragment Analyzer (Advanced 
Analytical Technologies). All cRNA targets were 
synthesized using the Illumina TotalPrep-96 RNA 
amplification Kit (Life Technologies) and fragmented 
according to the Affymetrix protocol, based on the 
Eberwine T7 procedure. Briefly, 200ng of total RNA 
were used to produce double-stranded cDNA, followed 
by in vitro transcription, and cRNA labeling with biotin. 
Then, 7.5μg of cRNA were hybridized on Affymetrix 
Rat 230 PM 96-Array in an Affymetrix GeneTitan 
device (Affymetrix, CA, USA) directly followed by 
staining and scanning in the same instrument. 
Affymetrix probes were normalized and summarized to 
probe sets using the Robust Multi-array Average 
(RMA) approach. We applied a non-specific filter to 
discard probe sets with low variability and retained 
15549 probe sets whose SD was greater than median of 
SD of all probe sets. Genes (represented by 15549 probe 
sets) were tested for differential expression using 
Limma for age, nerve type, and interaction term 
between age and nerve type [57]. We took into account 
that for each animal we had two nerve types by 
providing an estimate of the within-animal correlation 
via the duplicate Correlation function available in 
Limma [59]. We defined probe sets whose Benjamini-
Hoechberd adjusted p-value was lower than 0.05 as 
differentially expressed and exploited topGO to assess 
whether the DE probe sets were related to specific 
pathways. Raw data are available in GEO 
(http://www.ncbi.nlm.nih.gov/geo/) under accession 
number GSE77022.  
 
Reverse transcription and qPCR. Total RNA was 
extracted using a commercial kit (miRNeasy Mini Kit, 
Qiagen) according to the manufacturer’s instruction, 
and the concentration was measured using a NanoDrop 
device. Total RNA extracts were diluted at 20ng/ml and 
reverse transcribed into cDNA using the High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems) 
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and then diluted 1/2. Quantitative PCR reactions were 
performed using LightCycler DNA Green Master 
(Roche) on a LightCycler 384 Real-Time PCR System 
thermocycler (Roche). The amplification curves were 
analyzed by the LightCycler 480 SW 1.5 software. 
HPRT was amplified as qPCR normalization gene. 
 
Human clinical study. The human clinical study was 
approved by the University of Manchester Research 
Ethics Committee and was conducted in accordance 
with the Declaration of Helsinki. All participants 
provided written informed consent prior to inclusion in 
the study. Volunteers were included if they were male, 
and for the vastus lateralis aged between 18-35 years 
(mean (SD) age 25.2 (4.6) years, height 1.77 (0.06) m, 
body mass 74.8 (11.1) kg and BMI 23.7 (2.9) kg/m2) or 
65-90 years (mean (SD) age 71.6 (6.2) years, height 
1.72 (0.07) m, body mass 73.2 (8.7) kg and BMI 24.6 
(2.7) kg/m2). For the tibialis anterior (TA) they were 
aged between 18-35 years (mean (SD) age 27.5 (44.6) 
years, height 1.77 (0.05) m, body mass 76.7 (10.9) kg 
and BMI 24.5 (3.7) kg/m2) or 65-90 years (mean (SD) 
age 74.8 (7.6) years, height 1.71 (0.06) m, body mass 
74.7 (7.6) kg and BMI 25.9 (4.02) kg/m2). All 
participants were physically active and living 
independently. They were free from neuromuscular, 
metabolic and cardiovascular diseases (except for 
controlled hypertension), had not suffered a broken 
bone within the past two years and reported no mobility 
problems that affected their ability to complete usual 
activities of daily living. 
 
Muscle anatomical cross sectional area. Magnetic 
resonance imaging (MRI) was used to measure peak 
VL and TA muscle anatomical cross sectional areas 
using a T1-weighted turbo 3D sequence on a 0.25-T 
G-Scan (Esaote, Genoe, Italy). The motor point over 
the VL muscle belly was marked, and contiguous 
transverse-plane slices of 6mm thickness were 
collected. Images were analyzed off-line using Osirix 
imaging software (OsiriX medical imaging, OsiriX, 
Atlanta, USA) and the cross-sectional at the motor 
point was recorded. 
 
Surface EMG. The maximal compound muscle action 
potential (CMAP) was evoked by a manually triggered 
stimulator (model DS7A; Digitimer, Welwyn Garden 
City, Hertfordshire, UK) using percutaneous stimulation 
(Medserve, Daventry, UK). For VL, stimulation was 
applied to the femoral nerve and a carbon-rubber anode 
electrode (Dermatrode self-adhering electrode, 5.08cm 
diameter, Farmadomo, NL) was placed over the skin 
overlying the gluteus muscle. For TA, the anode was 
placed on the medial knee joint cleft and stimulation 
was applied to a superficial part of the common 
peroneal nerve on the lateral aspect of the shank close to 
the head of the fibula. For each muscle, the recording 
surface-EMG electrode was positioned over the motor 
point of the respective muscle belly to ensure the largest 
CMAP (negative peak amplitude) with fastest rise-time. 
For both VL and TA, the stimulator voltage was fixed at 
400V and the pulse width at 50μS, and the current was 
then increased incrementally until the CMAP negative 
peak amplitude plateaued. At this point the current was 
increased again by 30mA to ensure supra-maximal 
stimulation (usually occurring between 100 and 200mA 
for VL and 80-120mA for TA). 
 
Statistics. All genome wide statistical analyses were 
performed using R version 3.1.3 and relevant 
Bioconductor packages as described in the gene 
expression profiling section. All other statistical 
analyses were performed using the GraphPad Prism 
software, and statistical significance was assessed by 
the Mann-Whitney test for binary comparisons. For 
comparison of more than 2 groups, one-way ANOVA 
followed by Bonferroni’s multiple comparison test was 
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